We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Test Model Discriminates Ovarian Tumors

By LabMedica International staff writers
Posted on 28 Oct 2014
Print article
Image: Immunohistochemical staining of ovarian tissue with anti-CA125 for the diagnosis of ovarian carcinoma; the neoplastic cells are strongly stained (Photo courtesy of Epitomics).
Image: Immunohistochemical staining of ovarian tissue with anti-CA125 for the diagnosis of ovarian carcinoma; the neoplastic cells are strongly stained (Photo courtesy of Epitomics).
A new test can discriminate between benign and malignant ovarian tumors, and identify different types of carcinomatous tumors, with a high level of accuracy.

An accurate specific diagnosis of adnexal tumors before surgery will almost certainly improve the triage of patients and so increase the likelihood that patients will receive appropriate treatment.

An international team of scientists led by those at Katholieke Universiteit Leuven (Belgium) and the Imperial College London (UK) developed the test using data from 3,506 patients from 10 European countries from 1999 to 2007, that looks at which information available before the operation could be used to predict the diagnosis. They then tested the model on a further 2,403 patients between 2009 and 2012.

The test was the Assessment of Different NEoplasias in the adneXa (ADNEX) model that contains three clinical and six ultrasound predictors: age, serum CA-125 level, type of center (oncology centers versus other hospitals), maximum diameter of lesion, proportion of solid tissue, more than 10 cyst locules, number of papillary projections, acoustic shadows, and ascites.

Participating centers were encouraged to measure serum cancer antigen 125 (CA-125). They used second generation immunoradiometric assay kits for CA-125 II from several companies including Roche Diagnostics (Basel, Switzerland) , Centocor (Malvern, PA; USA), Cis-Bio (Codolet, France), and six other manufacturers. All these kits used the OC125 antibody. The reference standard was the histopathological diagnosis of the mass after surgical removal by laparotomy or laparoscopy.
The ADNEX model satisfactorily discriminated between benign and malignant tumors and offers fair to excellent discrimination between four types of ovarian malignancy. The use of ADNEX has the potential to improve triage and management decisions and so reduce morbidity and mortality associated with adnexal pathology.

Tom Bourne, MD, PhD, a professor of Surgery and Cancer, and a senior author of the study said, “It's very important to get the preoperative diagnosis right. If it isn't right, the patient might have a more extensive operation than they need, for example having an ovary removed unnecessarily. If a tumor is benign, a woman might not need any treatment at all. If it is malignant, you need to know what type of tumor it is to choose the best treatment and that treatment needs to be carried out by specialist gynecological cancer surgeon.” The study was published on October 15, 2014, in the British Medical Journal.

Related Links:

Katholieke Universiteit Leuven
Imperial College London 
Roche Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.